Alpha 2.0
Login Register
» Authors » Hassan Rahimi

Hassan Rahimi

Explore the profile of Hassan Rahimi including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 26
Citations 402
Followers 0
Related Specialties
Oncology
General Medicine
Allergy & Immunology
Top 10 Co-Authors
Aurelia Rughetti
Chiara Napoletano
Marianna Nuti
Ilaria Grazia Zizzari
Filippo Bellati
Andrea Botticelli
Fabio Scirocchi
Pierluigi Benedetti Panici
Morena Antonilli
Salvatore Caponnetto
Published In
Int J Mol Sci
Br J Haematol
Trauma Mon
Cancer Immunol Res
Int J Oncol
Affiliations
Soon will be listed here.
Recent Articles
1.
Targeting FGFRs by pemigatinib induces G1 phase cell cycle arrest, cellular stress and upregulation of tumor suppressor microRNAs
Pace A, Scirocchi F, Napoletano C, Zizzari I, Po A, Megiorni F, et al.
J Transl Med . 2023 Sep; 21(1):626. PMID: 37715207
Background: Fibroblast growth factor receptor (FGFR) gene family alterations are found in several cancers, indicating their importance as potential therapeutic targets. The FGFR-tyrosine kinase inhibitor (TKI) pemigatinib has been introduced...
2.
Circulating CD137 T Cell Levels Are Correlated with Response to Pembrolizumab Treatment in Advanced Head and Neck Cancer Patients
Cirillo A, Zizzari I, Botticelli A, Strigari L, Rahimi H, Scagnoli S, et al.
Int J Mol Sci . 2023 Apr; 24(8). PMID: 37108276
Pembrolizumab, an anti-PD-1 antibody, has been approved as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma ((R/M) HNSCC). However, only a minority of patients benefit from...
3.
Proteomic characterization of extracellular vesicles released by third stage larvae of the zoonotic parasite (Nematoda: Anisakidae)
Palomba M, Rughetti A, Mignogna G, Castrignano T, Rahimi H, Masuelli L, et al.
Front Cell Infect Microbiol . 2023 Apr; 13:1079991. PMID: 37009516
Introduction: is a sibling species within the (s.l.) complex requiring marine homeothermic (mainly cetaceans) and heterothermic (crustaceans, fish, and cephalopods) organisms to complete its life cycle. It is also a...
4.
Soluble PD-L1 as a Prognostic Factor for Immunotherapy Treatment in Solid Tumors: Systematic Review and Meta-Analysis
Scirocchi F, Strigari L, Di Filippo A, Napoletano C, Pace A, Rahimi H, et al.
Int J Mol Sci . 2022 Nov; 23(22). PMID: 36430974
Blocking the Programmed Cell Death Protein 1 (PD-1)/programmed death ligand-1 (PD-L1) axis has demonstrated great efficacy in cancer immunotherapy treatment and remains the central modality of immune targeting. To support...
5.
Constructing a novel competing Endogenous RNAs network based on NR3C1 and X-linked inhibitor of apoptosis protein genes reveals potential prognostic biomarkers in colorectal cancer
Abdolvand M, Sadeghi M, Emami M, Fahim A, Rahimi H, Amjadi E, et al.
J Res Med Sci . 2022 Nov; 27:71. PMID: 36353350
Background: Long noncoding RNAs (lncRNAs) have been recognized as the main modulatory molecules in various cancers and perform as competing endogenous RNAs (ceRNAs). The nuclear hormone receptor superfamily of ligand-activated...
6.
Glycan-Lectin Interactions as Novel Immunosuppression Drivers in Glioblastoma
Pace A, Scirocchi F, Napoletano C, Zizzari I, DAngelo L, Santoro A, et al.
Int J Mol Sci . 2022 Jun; 23(11). PMID: 35682991
Despite diagnostic and therapeutic improvements, glioblastoma (GB) remains one of the most threatening brain tumor in adults, underlining the urgent need of new therapeutic targets. Lectins are glycan-binding proteins that...
7.
IgM-Rheumatoid factor confers primary resistance to anti-PD-1 immunotherapies in NSCLC patients by reducing CD137T-cells
Ugolini A, Zizzari I, Ceccarelli F, Botticelli A, Colasanti T, Strigari L, et al.
EBioMedicine . 2020 Nov; 62:103098. PMID: 33166793
Background: ICIs have strongly improved the outcome of NSCLC patients. However, primary and secondary resistance occur during treatment in most of the patients, with several of them developing fast progressions....
8.
Soluble Immune Checkpoints, Gut Metabolites and Performance Status as Parameters of Response to Nivolumab Treatment in NSCLC Patients
Zizzari I, Di Filippo A, Scirocchi F, Di Pietro F, Rahimi H, Ugolini A, et al.
J Pers Med . 2020 Nov; 10(4). PMID: 33158018
Patients with non-small cell lung cancer (NSCLC) have been shown to benefit from the introduction of anti-PD1 treatment. However, not all patients experience tumor regression and durable response. The identification...
9.
Investigating Patterns of Immune Interaction in Ovarian Cancer: Probing the O-glycoproteome by the Macrophage Galactose-Like C-type Lectin (MGL)
Napoletano C, Steentoff C, Battisti F, Ye Z, Rahimi H, Zizzari I, et al.
Cancers (Basel) . 2020 Oct; 12(10). PMID: 33019700
Glycosylation, the posttranslational linking of sugar molecules to proteins, is notoriously altered during tumor transformation. More specifically in carcinomas, GalNAc-type -glycosylation, is characterized by biosynthetically immature truncated glycans present on...
10.
Bevacizumab-Based Chemotherapy Triggers Immunological Effects in Responding Multi-Treated Recurrent Ovarian Cancer Patients by Favoring the Recruitment of Effector T Cell Subsets
Napoletano C, Ruscito I, Bellati F, Zizzari I, Rahimi H, Gasparri M, et al.
J Clin Med . 2019 Mar; 8(3). PMID: 30889935
Increasing evidence strongly suggests that bevacizumab compound impacts the immunological signature of cancer patients and normalizes tumor vasculature. This study aims to investigate the correlation between the clinical response to...